Hims GLP 1 Deal With Novo Nordisk Reshapes Growth And Valuation Story [Yahoo! Finance]
Hims & Hers Health, Inc. Class A (HIMS)
Company Research
Source: Yahoo! Finance
Hims & Hers Health (NYSE:HIMS) is expanding access to FDA-approved GLP-1 medications through a new collaboration with Novo Nordisk. The company is introducing a comprehensive weight loss membership with new affordable pricing options tied to GLP-1 therapies. This move comes as Novo Nordisk rolls out a multi-month Wegovy subscription program through telehealth platforms. Hims & Hers Health, a direct-to-consumer telehealth company focused on personalized care and wellness products, is stepping deeper into the fast-growing prescription weight loss category. The new GLP-1 offering comes on top of earlier weight management initiatives and aligns the platform more closely with a leading obesity drug manufacturer in Novo Nordisk. For you as an investor, this combination of broader GLP-1 access, membership-based pricing, and integrated support services could reshape how Hims & Hers approaches long-term customer relationships in weight loss care. The partnership with Novo Nordisk also
Show less
Read more
Impact Snapshot
Event Time:
HIMS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
HIMS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
HIMS alerts
High impacting Hims & Hers Health, Inc. Class A news events
Weekly update
A roundup of the hottest topics
HIMS
News
- Hims & Hers Health (HIMS) had its price target lowered by TD Cowen from $25.00 to $23.00. They now have a "hold" rating on the stock.MarketBeat
- Novo Nordisk’s FDA-Approved GLP-1s Now Available With Hims & HersBusiness Wire
- Surging Oil Prices Spark Market Jitters [Yahoo! Finance]Yahoo! Finance
- HIMS Investors Have Opportunity to Join Hims & Hers Health, Inc. Fraud Investigation with the Schall Law FirmGlobeNewswire
- INSP vs. HIMS: Which Stock Should Value Investors Buy Now? [Yahoo! Finance]Yahoo! Finance
HIMS
Earnings
- 2/23/26 - Beat
HIMS
Sec Filings
- 3/27/26 - Form SCHEDULE
- 3/24/26 - Form 4
- 3/18/26 - Form 4
- HIMS's page on the SEC website